Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug612 | Blood samples (collection of 5 mL of blood in a dry tube) Wiki | 0.71 |
| drug3099 | Project ECHO Wiki | 0.71 |
| drug3787 | Stools Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D025241 | Spondylarthritis NIH | 0.41 |
| D001172 | Arthritis, Rheumatoid NIH | 0.19 |
| D001168 | Arthritis NIH | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 0.19 |
| HP:0001369 | Arthritis HPO | 0.16 |
Navigate: Correlations HPO
There are 2 clinical trials
This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time. After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data. The blood samples will be taken at 3 times: T0 (day of inclusion), between 6 weeks and 3 months and 6 months' post-inclusion. Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples. A questionnaire will be completed by the inclusion volunteer (T0) in the study then 1, between 6 weeks and 3 months and 6 months' post-inclusion. The nasopharyngeal swabs will be performed at 2 times: between 6 weeks and 3 months and 6 months post-inclusion for Institut Curie staff who have had at least one of the following three criteria on the sample or questionnaire carried out at T0: - have had RT-PCR+ - and/or presence of antibodies at the 95% threshold - and/or anosmia/ageusia - and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the three criteria above, a nasopharyngeal swab will be performed during the following visits. The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses. If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months and 6 months after inclusion. The nasopharyngeal swabs will be performed at 3 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, and 6 months post-inclusion
Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at inclusion Time: 1 dayDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 1 month Time: 1 monthDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 3 months Time: 3 monthsDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 6 months Time: 6 monthsDescription: Comparative performance of anti-SARS-CoV-2 antibody detection techniques (sensitivity and specificity of serological tests)
Measure: Comparative performance of anti-SARS-CoV-2 antibody detection techniques Time: 9 monthsDescription: Prevalence of immune subjects for SARS-CoV-2 in a well-defined active healthy population, working at the hospital or not, leading to variable exposure levels
Measure: Prevalence of immune subjects for SARS-CoV-2 Time: 3 monthsDescription: Nature and quantity of anti-SARS-CoV-2 antibodies: ImmunoglobulinM, ImmunoglobulinG and ImmunoglobulinA)
Measure: Nature and quantity of anti-SARS-CoV-2 antibodies Time: 3 monthsDescription: The analysis of the evolution of serology results over time will be done by a mixed model taking into account the repeated framework of the data of a subject
Measure: Evolution of the different antibodies against the SARS-CoV-2 virus over time. Time: 6 monthsDescription: Prevalence of Anti-covid IgA in volonteers RT/PCR+ and/or presence of antibodies at the 95 % threshold and/or COVID symptoms
Measure: Prevalence of Anti-covid IgA response in the nasal mucosa Time: 6 monthsThe purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.
Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: up to Day 30Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: between Day 30 and Day 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports